133 related articles for article (PubMed ID: 31077298)
1. Can We Find the Positive in Negative Clinical Trials?
Allegra CJ; Goodwin PJ; Ganz PA
J Natl Cancer Inst; 2019 Jul; 111(7):637-638. PubMed ID: 31077298
[No Abstract] [Full Text] [Related]
2. Emil Frei III, 1924-2013.
Holland JF; Freireich EJ
J Clin Oncol; 2013 Oct; 31(30):3727-30. PubMed ID: 24019548
[No Abstract] [Full Text] [Related]
3. Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
Trimble EL; Abrams JS; Ansher SS; Smith MA; Zwiebel JA; Tomaszewski JE
Future Med Chem; 2010 Apr; 2(4):555-9. PubMed ID: 21426005
[No Abstract] [Full Text] [Related]
4. The costs of cancer drugs.
Begg CB
Clin Trials; 2020 Apr; 17(2):118. PubMed ID: 32070133
[No Abstract] [Full Text] [Related]
5. Research probes anticancer mechanisms of Polyphenon E.
Graff S
J Natl Cancer Inst; 2009 May; 101(9):627-8. PubMed ID: 19401557
[No Abstract] [Full Text] [Related]
6. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.
Beitz J; Gnecco C; Justice R
J Natl Cancer Inst Monogr; 1996; (20):7-9. PubMed ID: 8750460
[TBL] [Abstract][Full Text] [Related]
7. Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.
Pinheiro SP; Rivera DR; Graham DJ; Freedman AN; Major JM; Penberthy L; Levenson M; Bradley MC; Wong HL; Ouellet-Hellstrom R
Ann Epidemiol; 2016 Nov; 26(11):735-740. PubMed ID: 27663208
[TBL] [Abstract][Full Text] [Related]
8. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.
Unger JM; Nghiem VT; Hershman DL; Vaidya R; LeBlanc M; Blanke CD
JAMA Netw Open; 2019 Sep; 2(9):e1910593. PubMed ID: 31483471
[TBL] [Abstract][Full Text] [Related]
9. Translational research in the National Cancer Institute's cooperative groups.
Symmans WF
Clin Adv Hematol Oncol; 2014 Nov; 12(11):785-7. PubMed ID: 25674720
[No Abstract] [Full Text] [Related]
10. The National Cancer Institute Experimental Therapeutics program.
Doroshow JH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):403-4. PubMed ID: 20733549
[No Abstract] [Full Text] [Related]
11. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
12. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
13. Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials.
Bonsu J; Charles L; Guha A; Awan F; Woyach J; Yildiz V; Wei L; Jneid H; Addison D
Circulation; 2019 May; 139(22):2594-2596. PubMed ID: 30882246
[No Abstract] [Full Text] [Related]
14. New NCI drug formulary cuts red tape.
Weintraub A
Lab Anim (NY); 2017 Jun; 46(7):285. PubMed ID: 28644447
[No Abstract] [Full Text] [Related]
15. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
Pignatti F; Hemmings R; Jonsson B
Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
[No Abstract] [Full Text] [Related]
16. When are "positive" clinical trials in oncology truly positive?
Ocana A; Tannock IF
J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
[TBL] [Abstract][Full Text] [Related]
17. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB
J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228
[TBL] [Abstract][Full Text] [Related]
18. Recasting cancer trials.
Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
[No Abstract] [Full Text] [Related]
19. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.
Printz C
Cancer; 2015 May; 121(10):1529-30. PubMed ID: 25946212
[No Abstract] [Full Text] [Related]
20. Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview.
Kapetanovic IM
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):698-700. PubMed ID: 19240231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
